NDC product
Glyxambi
NDC 0597-0182 · Boehringer Ingelheim Pharmaceuticals, Inc.
Key facts
| Product NDC | 0597-0182 |
|---|---|
| Proprietary name | Glyxambi |
| Nonproprietary name | empagliflozin and linagliptin |
| Substances | EMPAGLIFLOZIN, LINAGLIPTIN |
| Dosage form | TABLET, FILM COATED |
| Route | ORAL |
| Labeler | Boehringer Ingelheim Pharmaceuticals, Inc. |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Application number | NDA206073 |
| Pharmacologic classes | Dipeptidyl Peptidase 4 Inhibitor [EPC], Dipeptidyl Peptidase 4 Inhibitors [MoA], Sodium-Glucose Cotransporter 2 Inhibitor [EPC], Sodium-Glucose Transporter 2 Inhibitors [MoA] |
| Marketing start | Jan 30, 2015 |
| Listing certified through | Dec 31, 2027 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: